Teva will be one of five generic firms in U.S. following industry consolidation, company's Fletcher predicts.
Executive Summary
TEVA PREDICTS U.S. GENERIC INDUSTRY WILL CONSOLIDATE INTO FIVE FIRMS at most with significant market presence, Teva President of U.S. Operations William Fletcher told a recent Alex. Brown healthcare conference in Baltimore. "We believe that after consolidation there will perhaps be less than five large manufacturers dominating the industry," he said. "We fully intend to be one of those leaders."